Wall Street analysts forecast that AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will announce $91.24 million in sales for the current quarter, according to Zacks. Four analysts have made estimates for AMAG Pharmaceuticals’ earnings. The highest sales estimate is $96.08 million and the lowest is $89.18 million. AMAG Pharmaceuticals posted sales of $146.36 million during the same quarter last year, which suggests a negative year-over-year growth rate of 37.7%. The business is scheduled to issue its next quarterly earnings report on Thursday, May 2nd.

On average, analysts expect that AMAG Pharmaceuticals will report full-year sales of $359.63 million for the current fiscal year, with estimates ranging from $336.25 million to $386.41 million. For the next financial year, analysts anticipate that the company will report sales of $347.51 million, with estimates ranging from $292.71 million to $384.31 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for AMAG Pharmaceuticals.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings results on Thursday, February 7th. The specialty pharmaceutical company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.38. The firm had revenue of $88.10 million for the quarter, compared to analysts’ expectations of $95.21 million. AMAG Pharmaceuticals had a negative return on equity of 17.10% and a negative net margin of 13.07%. The business’s revenue was down 31.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.10 earnings per share.

Several analysts have recently commented on the company. Cantor Fitzgerald restated a “neutral” rating on shares of AMAG Pharmaceuticals in a report on Friday, November 23rd. B. Riley restated a “buy” rating and set a $20.50 target price (down previously from $29.00) on shares of AMAG Pharmaceuticals in a report on Friday, December 14th. Zacks Investment Research upgraded AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 23rd. ValuEngine cut AMAG Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, February 15th. Finally, BidaskClub upgraded AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, January 5th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $20.21.

Institutional investors and hedge funds have recently modified their holdings of the company. Pearl River Capital LLC acquired a new position in shares of AMAG Pharmaceuticals during the fourth quarter valued at $28,000. Quantamental Technologies LLC acquired a new position in shares of AMAG Pharmaceuticals during the fourth quarter valued at $107,000. Tower Research Capital LLC TRC acquired a new position in shares of AMAG Pharmaceuticals during the third quarter valued at $173,000. First Quadrant L P CA acquired a new position in shares of AMAG Pharmaceuticals during the fourth quarter valued at $141,000. Finally, Municipal Employees Retirement System of Michigan acquired a new position in shares of AMAG Pharmaceuticals during the fourth quarter valued at $151,000.

Shares of AMAG stock traded up $0.01 during trading hours on Wednesday, hitting $12.47. 620,455 shares of the company’s stock were exchanged, compared to its average volume of 769,954. The company has a debt-to-equity ratio of 0.35, a quick ratio of 3.01 and a current ratio of 3.17. The stock has a market capitalization of $432.18 million, a PE ratio of -3.21 and a beta of 0.44. AMAG Pharmaceuticals has a 52 week low of $10.70 and a 52 week high of $26.10.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Further Reading: How are institutional investors different from individual investors?

Get a free copy of the Zacks research report on AMAG Pharmaceuticals (AMAG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.